Trial Profile
A two-cohort phase I/II trial of PTK787 and pemetrexed with or without cisplatin in patients with advanced non-small cell lung cancers and malignant pleural mesotheliomas.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Vatalanib (Primary) ; Cisplatin; Pemetrexed
- Indications Mesothelioma; Non-small cell lung cancer
- Focus Adverse reactions
- 16 Mar 2012 Planned End Date changed from 1 Sep 2006 to 1 Aug 2008 as reported by ClinicalTrials.gov.
- 16 Mar 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 04 Nov 2006 New trial record.